Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.

Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, Chen X, Shaw GM, Barouch DH, Haigwood NL, Corey L, Burton DR, Roederer M, Gilbert PB, Mascola JR, Huang Y.

Cell Host Microbe. 2019 Sep 11;26(3):336-346.e3. doi: 10.1016/j.chom.2019.08.014.

PMID:
31513771
2.

Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.

Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, Dussupt V, Itri V, Fox A, Shapiro MB, Pandey S, Cheever T, Fuller DH, Park B, Krebs SJ, Totrov M, Haigwood NL, Kong XP, Zolla-Pazner S.

Cell Rep. 2019 Jul 23;28(4):877-895.e6. doi: 10.1016/j.celrep.2019.06.074.

3.

Antibodies Tip the Balance Towards an HIV Cure.

Haigwood NL, Hessell AJ.

Trends Immunol. 2019 May;40(5):375-377. doi: 10.1016/j.it.2019.03.008.

PMID:
31030743
4.

IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Sarkar S, Piepenbrink MS, Basu M, Thakar J, Keefer MC, Hessell AJ, Haigwood NL, Kobie JJ.

Vaccine. 2019 Apr 17;37(17):2322-2330. doi: 10.1016/j.vaccine.2019.03.044. Epub 2019 Mar 27.

5.

Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques.

Matchett WE, Anguiano-Zarate SS, Nehete PN, Shelton K, Nehete BP, Yang G, Dorta-Estremera S, Barnette P, Xiao P, Byrareddy SN, Villinger F, Hessell AJ, Haigwood NL, Sastry KJ, Barry MA.

J Virol. 2019 May 1;93(10). pii: e02016-18. doi: 10.1128/JVI.02016-18. Print 2019 May 15.

PMID:
30842321
6.

Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.

Hessell AJ, Shapiro MB, Powell R, Malherbe DC, McBurney SP, Pandey S, Cheever T, Sutton WF, Kahl C, Park B, Zolla-Pazner S, Haigwood NL.

J Virol. 2018 May 14;92(11). pii: e02198-17. doi: 10.1128/JVI.02198-17. Print 2018 Jun 1.

7.

Passive and active antibody studies in primates to inform HIV vaccines.

Hessell AJ, Malherbe DC, Haigwood NL.

Expert Rev Vaccines. 2018 Feb;17(2):127-144. doi: 10.1080/14760584.2018.1425619. Epub 2018 Jan 19. Review.

8.

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques.

Jaworski JP, Bryk P, Brower Z, Zheng B, Hessell AJ, Rosenberg AF, Wu TT, Sanz I, Keefer MC, Haigwood NL, Kobie JJ.

PLoS One. 2017 Feb 21;12(2):e0172524. doi: 10.1371/journal.pone.0172524. eCollection 2017.

9.

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, Nadas A, Kong XP, Zolla-Pazner S, Hioe CE.

Vaccine. 2017 Mar 7;35(10):1464-1473. doi: 10.1016/j.vaccine.2016.11.107. Epub 2017 Feb 6.

10.

Use of broadly neutralizing antibodies for HIV-1 prevention.

Pegu A, Hessell AJ, Mascola JR, Haigwood NL.

Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511. Review.

11.

Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Hessell AJ, McBurney S, Pandey S, Sutton W, Liu L, Li L, Totrov M, Zolla-Pazner S, Haigwood NL, Gorny MK.

Vaccine. 2016 May 23;34(24):2713-21. doi: 10.1016/j.vaccine.2016.04.027. Epub 2016 Apr 19.

12.

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.

Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, Reed J, Sutton WF, Hammond KB, Cheever TA, Barnette PT, Legasse AW, Planer S, Stanton JJ, Pegu A, Chen X, Wang K, Siess D, Burke D, Park BS, Axthelm MK, Lewis A, Hirsch VM, Graham BS, Mascola JR, Sacha JB, Haigwood NL.

Nat Med. 2016 Apr;22(4):362-8. doi: 10.1038/nm.4063. Epub 2016 Mar 21.

13.

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.

J Immunol. 2016 Apr 1;196(7):3064-78. doi: 10.4049/jimmunol.1500527. Epub 2016 Mar 4.

14.

Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies.

Kobie JJ, Zheng B, Piepenbrink MS, Hessell AJ, Haigwood NL, Keefer MC, Sanz I.

Monoclon Antib Immunodiagn Immunother. 2015 Apr;34(2):65-72. doi: 10.1089/mab.2014.0064.

15.

Animal models in HIV-1 protection and therapy.

Hessell AJ, Haigwood NL.

Curr Opin HIV AIDS. 2015 May;10(3):170-6. doi: 10.1097/COH.0000000000000152. Review.

16.

Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Malherbe DC, Pissani F, Sather DN, Guo B, Pandey S, Sutton WF, Stuart AB, Robins H, Park B, Krebs SJ, Schuman JT, Kalams S, Hessell AJ, Haigwood NL.

J Virol. 2014 Nov;88(22):12949-67. doi: 10.1128/JVI.01812-14. Epub 2014 Sep 10.

17.

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.

Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, Stamatatos L.

J Virol. 2014 Nov;88(22):12968-81. doi: 10.1128/JVI.01816-14. Epub 2014 Aug 13.

18.

The MHC class II cofactor HLA-DM interacts with Ig in B cells.

Macmillan H, Strohman MJ, Ayyangar S, Jiang W, Rajasekaran N, Spura A, Hessell AJ, Madec AM, Mellins ED.

J Immunol. 2014 Sep 15;193(6):2641-2650. doi: 10.4049/jimmunol.1400075. Epub 2014 Aug 6.

19.

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.

Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, Zheng B, Legasse A, Park B, Dickerson M, Lewis AD, Colgin LM, Axthelm M, Messaoudi I, Sacha JB, Burton DR, Forthal DN, Hessell AJ, Haigwood NL.

J Virol. 2013 Oct;87(19):10447-59. doi: 10.1128/JVI.00049-13. Epub 2013 Jul 24.

20.

Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography.

Moldt B, Saye-Francisco K, Schultz N, Burton DR, Hessell AJ.

Methods. 2014 Jan 1;65(1):127-32. doi: 10.1016/j.ymeth.2013.06.022. Epub 2013 Jun 25.

21.

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR.

J Virol. 2012 Jun;86(11):6189-96. doi: 10.1128/JVI.00491-12. Epub 2012 Mar 28.

22.

Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.

Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK.

J Virol. 2012 Mar;86(6):2930-41. doi: 10.1128/JVI.06349-11. Epub 2012 Jan 11.

23.

Neutralizing antibodies and control of HIV: moves and countermoves.

Hessell AJ, Haigwood NL.

Curr HIV/AIDS Rep. 2012 Mar;9(1):64-72. doi: 10.1007/s11904-011-0105-5. Review.

PMID:
22203469
24.

A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, Poignard P, Hessell AJ, Burton DR.

J Virol. 2011 Oct;85(20):10572-81. doi: 10.1128/JVI.05541-11. Epub 2011 Aug 17.

25.

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6. doi: 10.1073/pnas.1103012108. Epub 2011 Jun 20.

26.

Design, synthesis, and biological evaluation of a biyouyanagin compound library.

Nicolaou KC, Sanchini S, Sarlah D, Lu G, Wu TR, Nomura DK, Cravatt BF, Cubitt B, de la Torre JC, Hessell AJ, Burton DR.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6715-20. doi: 10.1073/pnas.1015258108. Epub 2011 Jan 18.

27.

Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus.

Weinfurter JT, May GE, Soma T, Hessell AJ, León EJ, Macnair CE, Piaskowski SM, Weisgrau K, Furlott J, Maness NJ, Reed J, Wilson NA, Rakasz EG, Burton DR, Friedrich TC.

J Virol. 2011 Jan;85(1):530-41. doi: 10.1128/JVI.01025-10. Epub 2010 Oct 20.

28.

Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.

Reynolds MR, Weiler AM, Piaskowski SM, Kolar HL, Hessell AJ, Weiker M, Weisgrau KL, León EJ, Rogers WE, Makowsky R, McDermott AB, Boyle R, Wilson NA, Allison DB, Burton DR, Koff WC, Watkins DI.

J Virol. 2010 Sep;84(18):9190-9. doi: 10.1128/JVI.00041-10. Epub 2010 Jun 30.

29.

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.

J Gen Virol. 2010 May;91(Pt 5):1354-64. doi: 10.1099/vir.0.017319-0. Epub 2010 Jan 6.

PMID:
20053822
30.

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD.

Science. 2009 Nov 20;326(5956):1123-7. doi: 10.1126/science.1175868.

31.

Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein.

Lee JE, Fusco ML, Abelson DM, Hessell AJ, Burton DR, Saphire EO.

Acta Crystallogr D Biol Crystallogr. 2009 Nov;65(Pt 11):1162-80. doi: 10.1107/S0907444909032314. Epub 2009 Oct 22.

32.

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR.

J Virol. 2010 Feb;84(3):1302-13. doi: 10.1128/JVI.01272-09. Epub 2009 Nov 11.

33.

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR.

Nat Med. 2009 Aug;15(8):951-4. doi: 10.1038/nm.1974. Epub 2009 Jun 7.

34.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

35.

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.

Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO.

Nature. 2008 Jul 10;454(7201):177-82. doi: 10.1038/nature07082.

36.

Fc receptor but not complement binding is important in antibody protection against HIV.

Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.

Nature. 2007 Sep 6;449(7158):101-4.

PMID:
17805298
37.

Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region.

Mantis NJ, Palaia J, Hessell AJ, Mehta S, Zhu Z, Corthésy B, Neutra MR, Burton DR, Janoff EN.

J Immunol. 2007 Sep 1;179(5):3144-52.

38.

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD.

Nature. 2007 Feb 15;445(7129):732-7.

39.

Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay.

Meissner F, Maruyama T, Frentsch M, Hessell AJ, Rodriguez LL, Geisbert TW, Jahrling PB, Burton DR, Parren PW.

Virology. 2002 Sep 1;300(2):236-43.

40.

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW.

J Virol. 2001 Dec;75(24):12161-8.

41.

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR.

J Virol. 2001 Sep;75(17):8340-7.

42.

Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia.

Dorrell L, Hessell AJ, Wang M, Whittle H, Sabally S, Rowland-Jones S, Burton DR, Parren PW.

AIDS. 2000 Jun 16;14(9):1117-22.

PMID:
10894275

Supplemental Content

Loading ...
Support Center